SciSparc & Clearmind Patent for Cocaine Addiction
Ticker: SPRC · Form: 6-K · Filed: Mar 11, 2025 · CIK: 1611746
| Field | Detail |
|---|---|
| Company | Scisparc Ltd. (SPRC) |
| Form Type | 6-K |
| Filed Date | Mar 11, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: patent, psychedelics, collaboration, addiction-treatment
TL;DR
SciSparc patent filed in South Korea for cocaine addiction treatment using psychedelics.
AI Summary
SciSparc Ltd. announced on March 10, 2025, that its collaboration with Clearmind has led to the publication of a patent application in South Korea for a psychedelic combination treatment targeting cocaine addiction. This development stems from their ongoing research and development efforts in the psychedelic therapeutics space.
Why It Matters
This patent application signifies progress in developing novel treatments for addiction, potentially opening new therapeutic avenues and market opportunities for SciSparc.
Risk Assessment
Risk Level: medium — The filing is a patent application publication, which is a positive step but does not guarantee market approval or commercial success.
Key Players & Entities
- SciSparc Ltd. (company) — Filer of the report and subject of the announcement.
- Clearmind (company) — Collaborating company with SciSparc on the patent application.
- South Korea (location) — Jurisdiction where the patent application was published.
- March 10, 2025 (date) — Date of the press release announcing the patent application publication.
FAQ
What is the specific psychedelic combination treatment mentioned in the patent application?
The filing does not specify the exact psychedelic combination but refers to it as a 'psychedelic combination treatment' for cocaine addiction.
What is the current status of this patent application in South Korea?
The patent application has been published in South Korea as of March 10, 2025.
What is SciSparc Ltd.'s role in this collaboration?
SciSparc Ltd. is collaborating with Clearmind on the development and publication of this patent application.
Does this patent application guarantee regulatory approval for the treatment?
No, a patent application publication does not guarantee regulatory approval for the treatment; it protects the intellectual property.
What is the primary indication for the treatment covered by this patent application?
The primary indication is cocaine addiction.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 11, 2025 regarding SciSparc Ltd. (SPRC).